Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
January 31, 2020 09:26 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
June 04, 2019 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement...
A Emergent BioSolutions anuncia a concessão de autorização de introdução no mercado em cinco países da UE da sua vacina por via oral contra a febre tifoide; expande a disponibilidade na Europa
May 20, 2019 16:05 ET
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- A Emergent BioSolutions Inc. (NYSE: EBS) anunciou hoje que foi bem-sucedida na obtenção da autorização de introdução no mercado da sua vacina...
Emergent BioSolutions gibt Genehmigung der Marktzulassung in fünf EU-Ländern für seinen oralen Typhus-Impfstoff bekannt; Ausweitung der Verfügbarkeit in Europa
May 20, 2019 16:05 ET
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) gab heute bekannt, dass es erfolgreich die Marktzulassung für seinen oralen Typhus-Impfstoff...
Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe
May 20, 2019 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine...
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
April 16, 2019 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and...